NAVLIN Daily NewsCheckout Today’s News
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problemsIt is the first new product cleared under the FDA’s controversial Commissioner’s National Priority Voucher (CNPV) program, and will begin shipping to patients on April 6Eligible commercially insured patients may pay $25 per month with the Foundayo savings card, while self-pay pricing starts at $149 per month for the lowest dose and eligible Medicare Part D beneficiaries may access the treatment for $50 per month from July 1, 2026
In a final draft guidance, the UK's National Institute for Health and Care Excellence (NICE) has recommended Novo Nordisk’s Wegovy (semaglutide) for cardiovascular risk reduction, as an add-on to standard care in high-risk patientsEvidence from the phase III SELECT trial showed a 20% reduction in major cardiovascular events with Wegovy versus placebo, supporting its clinical benefit and cost-effectiveness for the NHSAccording to NICE’s document, the list price of Wegovy varies by dose, ranging from £73.25 to £175.80 per pack (excluding VAT)
Novo Nordisk has slashed prices of its diabetes and weight-loss drugs, Ozempic and Wegovy, in India by up to 36% and 48%, respectively, as it faces growing competition from cheaper generic versionsIndia’s market is shifting quickly after the patent expiry, with companies including Dr. Reddy's Laboratories, Zydus Lifesciences, Sun Pharmaceutical Industries, and Torrent Pharma, launching generic semaglutide drugs priced up to 70% lower in some casesThe company had already cut Wegovy prices by up to 37% last year in anticipation of increased generic competition
According to STAT News, the Trump administration now has legislative text to codify its voluntary Most Favored Nation (MFN) drug pricing deals and is looking to meet with manufacturers to discuss the proposalAlthough the text has not yet been made public, according to a White House official, the draft proposal closely follows the outlines of the voluntary deals the administration has struck with pharmaceutical companies so far. Additionally, the legislation includes a provision that would allow medicines purchased in cash through direct-to-patient (DTP) programs to count toward a patient’s deductibleHowever, the Trump administration continues to run into opposition from both manufacturers and members of Congress
Last week, NAVLIN Daily covered key developments across the globe, including new findings on TrumpRx prices, South Korea approving its drug pricing reforms, and Spain facing scrutiny over pricing transparency Italy moved to simplify price and reimbursement negotiations, while the Spanish government tabled an amendment to keep drug prices secret in response to U.S. MFN pricing In India, semaglutide prices crashed to around USD 15 per month following the March 2026 patent expiry
Germany’s Health Finance Commission (FKG) has presented its report on recommendations to stabilize the contribution rates in the statutory health insurance (GKV) from 2027The FKG highlights that pharmaceutical spending is being driven not by increasing prescription volumes, but by the escalating prices of newer, patent-protected medicines. As a result, among 66 recommendations, the group calls for tighter price–volume agreements, which would trigger automatic price reductions when sales exceed agreed thresholds, and a rework of the Drug Market Reorganization Act (AMNOG), such as abolishing orphan drug privilegesSpeaking during a press briefing, Federal Health Minister Nina Warken noted: “We will select suitable measures from [the Commission's report]. I can imagine that other proposals might emerge during the drafting or discussion process. But the foundation, the major foundation, the broad basis of these proposals from the Commission, offer us a good selection, and are well-assessed, and their evaluations are transparent”
At EPA Congress 2026 in Amsterdam, Anna Smith, NAVLIN Daily's Head of News, spoke with Maria Eriksson, medical assessor at Sweden's Dental and Pharmaceutical Benefits Agency (TLV)Eriksson presented at the congress, noting that Nordic authorities believe they are well prepared for the transition to joint EU HTA, owing to their longstanding involvement in European HTA cooperationStay tuned as we publish interviews with other speakers and experts we interviewed at EPA
South Korea approved its first large-scale drug pricing reform in over a decade, slashing generic drug reimbursement from 53.55% to 45% of the originator price. The move aims to cut national drug costs, boost funds for innovation, and align high domestic generic prices to match OECD normsKey perks under the reform include premium pricing for pediatric drugs, antibiotics, and those using local ingredients, along with incentives for innovative firmsThe Korea Global Pharmaceutical Industry Association (KRPIA) welcomed improvements like faster listings for rare disease treatments and flexible pricing but acknowledged industry concerns. An emergency panel continues to fear that the deep generic price cuts and rising raw material costs could destabilize the market. It called for policy flexibility to protect innovation and health security
The High Health Authority (HAS) of France is in favor of reimbursing Insmed’s Brinsupri (brensocatib) for the treatment of non–cystic fibrosis bronchiectasis in patients aged 12 years and older who have experienced at least two exacerbations in the previous 12 monthsTo help HAS come to a decision, the Transparency Committee (TC) looked at data from the Phase III ASPEN trial and the Phase II WILLOW study, both randomized, double-blind, placebo-controlled trialsHAS determined the medical service (SMR) provided by Brinsupri is “Moderate,” while the actual therapeutic benefit is “Absence V” with a proposed reimbursement rate of 30%
The Korean National Assembly approved the drug pricing reform plan, opening the doors to its final review by the Health Insurance Policy Deliberation Committee on Thursday. The plan includes lowering the price reduction rate for generic and off-patent drugs to the "low to mid-40%" range, far from the industry's proposed rate of 48.2%Lawmakers debated countermeasures for the potential fallout, such as drugmakers cutting costs via CSO partnerships. They also discussed revising the 1+3 system (which allows generics to share bioequivalence data), price premium incentives for generics from certified innovative firms, preferential pricing for critical drug producers to stabilize supply, and extending the stepwise pricing system’s start from the 11th to the 13th productIndustry concerns were largely ignored despite requests for consultation. The reform’s steep cuts may force domestic companies to implement drastic cost-saving measures that could ripple across the drug supply chain
650+
+99%
<24
4,000+
24x7
99.5%
